News Column

Findings from Tokyo Medical and Dental University in Stem Cells Reported (Status and Prospects of Liver Cirrhosis Treatment by Using Bone...

July 16, 2014



Findings from Tokyo Medical and Dental University in Stem Cells Reported (Status and Prospects of Liver Cirrhosis Treatment by Using Bone Marrow-Derived Cells and Mesenchymal Cells)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Stem Cell Research have been published. According to news originating from Tokyo, Japan, by NewsRx correspondents, research stated, "In 2003, we started autologous bone marrow cell infusion (ABMi) therapy for treating liver cirrhosis. ABMi therapy uses 400mL of autologous bone marrow obtained under general anesthesia and infused mononuclear cells from the peripheral vein."

Our news journalists obtained a quote from the research from Tokyo Medical and Dental University, "The clinical study expanded and we treated liver cirrhosis induced by HCV and HBV infection and alcohol consumption. We found that the ABMi therapy was effective for cirrhosis patients and now we are treating patients with combined HIV and HCV infection and with metabolic syndrome-induced liver cirrhosis. Currently, to substantiate our findings that liver cirrhosis can be successfully treated by the ABMi therapy, we are conducting randomized multicenter clinical studies designated `` Advanced medical technology B'' for HCV-related liver cirrhosis in Japan. On the basis of our clinical study, we developed a proof-of-concept showing that infusion of bone marrow cells (BMCs) improved liver fibrosis and sequentially activated proliferation of hepatic progenitor cells and hepatocytes, further promoting restoration of liver functions. To treat patients with severe forms of liver cirrhosis, we continued translational research to develop less invasive therapies by using mesenchymal stem cells derived from bone marrow. We obtained a small quantity of BMCs under local anesthesia and expanded them into mesenchymal stem cells that will then be used for treating cirrhosis."

According to the news editors, the research concluded: "In this review, we present our strategy to apply the results of our laboratory research to clinical studies."

For more information on this research see: Status and Prospects of Liver Cirrhosis Treatment by Using Bone Marrow-Derived Cells and Mesenchymal Cells. Tissue Engineering Part B-Reviews, 2014;20(3):206-210. Tissue Engineering Part B-Reviews can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA (see also Stem Cell Research).

The news correspondents report that additional information may be obtained from S. Terai, Tokyo Medical & Dental University, Medical Res Inst, Dept. of Dev & Regenerat Biol, Tokyo, Japan. Additional authors for this research include T. Takami, N. Yamamoto, K. Fujisawa, T. Ishikawa, Y. Urata, H. Tanimoto, T. Iwamoto, Y. Mizunaga, T. Matsuda, T. Oono, M. Marumoto, G. Burganova, L.F. Quintanilha, I. Hidaka, Y. Marumoto, I. Saeki, K. Uchida, T. Yamasaki and Tan.

Keywords for this news article include: Asia, Tokyo, Japan, Therapy, Anesthesia, Hepatology, Bone Marrow, Bone Research, Immune System, Pain Medicine, Liver Diseases, Liver Cirrhosis, Gastroenterology, Stem Cell Research, Mesenchymal Stem Cells, Digestive System Diseases

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters